Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
By Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger
Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)
By Prakash S. Masand, MD, James Eudicone, MS, Andrei Pikalov, MD, PhD, Robert D. McQuade, PhD, Ronald N. Marcus, MD, Estelle Vester-Blokland, MD and Berit X. Carlson, PhD